Drug intelligence / Profile preview

Modified Xianyaoyin

Development stage: Preclinical
Lead developer: Capital’s Funds for Health Improvement and Research
Administration: Oral

Overview

Modified Xianyaoyin is a traditional Chinese medicine formulation presented in granule form. It is currently being investigated in a multicenter, randomized controlled trial for its efficacy and safety in patients with mild to moderate hypertriglyceridemia. The drug is administered orally, twice daily, over a 12-week course of treatment. The specific mechanism of action for its effects on triglyceride levels is part of the ongoing research.

Other names: 加减仙药饮

Beyond the preview

Go deeper on Modified Xianyaoyin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modified Xianyaoyin.

Explore the full profile